Short- versus long-course therapy in gram-negative bacilli bloodstream infections.
Adolescent
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents
/ pharmacology
Bacteremia
/ diagnosis
Cohort Studies
Female
Gram-Negative Bacteria
/ drug effects
Gram-Negative Bacterial Infections
/ drug therapy
Humans
Male
Middle Aged
Prospective Studies
Risk Factors
Time Factors
Treatment Outcome
Young Adult
Antimicrobial stewardship
Bloodstream infection therapy
Gram-negative bacteremia
Shorter therapy
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
15
11
2018
accepted:
02
01
2019
pubmed:
27
1
2019
medline:
24
9
2019
entrez:
26
1
2019
Statut:
ppublish
Résumé
Bacteremia due to gram-negative bacilli (GNB) is one of the most frequent causes of admission and prolongation of hospital stay. Nevertheless, optimal duration of antibiotic treatment is not clearly established. We designed an observational, prospective study of a cohort of adult patients with uncomplicated GNB bacteremia. They were classified according to the duration of treatment in short (7-10 days) or long (> 10 days) course. Mortality and bacteremia recurrence rate were evaluated, and propensity score for receiving short-course treatment was calculated. A total of 395 patients met eligibility criteria including 232 and 163 who received long- and short-course therapy, respectively. Median age was 71 years, 215 (54.4% male) and 51% had a urinary source. Thirty-day mortality was 12%. In multivariate analysis by logistic regression stratified according to propensity score quartile for receiving short-course therapy showed no association of duration of treatment with 30-day mortality or 90-day recurrence rate. Based on the results observed in our cohort, short-course therapy could be as safe and effective as longer courses.
Identifiants
pubmed: 30680566
doi: 10.1007/s10096-019-03467-5
pii: 10.1007/s10096-019-03467-5
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
851-857Références
Scand J Infect Dis. 2001;33(3):188-93
pubmed: 11303808
Ann Intern Med. 2002 Nov 19;137(10):791-7
pubmed: 12435215
J Antimicrob Chemother. 2003 Nov;52(5):849-52
pubmed: 14519681
Am J Infect Control. 2005 Aug;33(6):333-40
pubmed: 16061139
Am J Infect Control. 2008 Jun;36(5):309-32
pubmed: 18538699
Shock. 2009 Feb;31(2):146-50
pubmed: 18636041
Medicine (Baltimore). 2009 Mar;88(2):77-82
pubmed: 19282697
Clin Infect Dis. 2009 Jul 1;49(1):1-45
pubmed: 19489710
Crit Care. 2011;15(6):R267
pubmed: 22085732
PLoS One. 2012;7(12):e52349
pubmed: 23285002
Clin Microbiol Infect. 2013 Jun;19(6):501-9
pubmed: 23473333
J Antimicrob Chemother. 2014 Mar;69(3):779-85
pubmed: 24159153
Ann Hematol. 2014 May;93(5):785-90
pubmed: 24288110
Can J Infect Dis Med Microbiol. 2013 Fall;24(3):129-37
pubmed: 24421823
Int J Infect Dis. 2014 Sep;26:83-7
pubmed: 25008770
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
J Antimicrob Chemother. 2017 Jan;72(1):299-304
pubmed: 27986899
Infection. 2017 Oct;45(5):613-620
pubmed: 28478600
Clin Infect Dis. 2018 Jan 6;66(2):172-177
pubmed: 29190320
Clin Microbiol Infect. 2018 Oct;24(10):1077-1083
pubmed: 29371138
Enferm Infecc Microbiol Clin. 2018 Feb;36(2):112-119
pubmed: 29412895
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
J Clin Microbiol. 1994 Mar;32(3):710-4
pubmed: 7910828